Upgrade to SI Premium - Free Trial

Pfizer (PFE) Announces Prelim. Results from Proof-of-Concept Phase 2 Study of 20-Valent Pneumococcal Conjugate Vaccine Candidate

September 9, 2019 8:01 AM
Pfizer Inc. (NYSE: PFE) announced today positive preliminary results following administration of three doses in a four-dose series for a ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Corporate News FDA Management Comments

Next Articles